Skip to content

Kodiak Sciences

US · KOD #1934 by market cap Listed 2018
97.17 -0.73 -0.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

About Kodiak Sciences

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Founded
2009
CEO
Dr. Victor Perlroth, M.D.
Employees
124
Headquarters
Palo Alto, California, United States of America
Fiscal year end
12-31
Website
kodiak.com

Company profile

Exchange
US
Symbol
KOD
Market-cap rank
#1934
Listing date
2018-10-04
Market cap
6.35B
Float cap
3.82B
Shares out
65.40M
Float shares
39.27M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:57:11 · For reference only, not investment advice and not tailored to your situation.

Kodiak Sciences discussion 0 comments

Add a comment